MedTrace Logo

Glycine vs Placebo for the Schizophrenia Prodrome

NCT00291226 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-04-02

Study results available
· View outcomes & findings →

Summary

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

Conditions

  • Schizophrenia Prodrome

Interventions

DRUG

Glycine

Glycine 0.4 g/kg bid

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Glytech, Inc

    collaborator INDUSTRY

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Scott W Woods, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291226 on ClinicalTrials.gov